Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings as of Jun 27, 2018

June 27, 2018 - By Lindsey Price

During Q1 2018 the big money sentiment decreased to 1.19. That’s change of 0.01, from 2017Q4’s 1.2. 18 investors sold all, 46 reduced holdings as Aerie Pharmaceuticals, Inc. ratio turned negative. 59 grew holdings while 17 funds acquired holdings. Funds hold 39.43 million shares thus 13.11% more from 2017Q4’s 34.86 million shares.
Moreover, Fincl Consulate Inc has 0.3% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 10,500 shs. Alps Advisors stated it has 50,556 shs or 0.02% of all its holdings. 70,668 were reported by Senzar Asset Ltd Liability. Glenmede Tru Na, Pennsylvania-based fund reported 714 shs. Northern Corp has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 433,548 shs. Morgan Stanley holds 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 786,970 shs. Pub Employees Retirement Association Of Colorado invested in 0% or 2,940 shs. The Nebraska-based Ameritas Partners has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Raymond James Associates holds 0% or 25,454 shs. Walleye Trading Ltd Limited Liability Company reported 42 shs or 0% of all its holdings. Tiaa Cref Invest Limited Liability stated it has 90,392 shs or 0% of all its holdings. Jgp Gestao De Recursos Ltda accumulated 0.3% or 13,844 shs. Highland Capital Management Limited Partnership stated it has 0.46% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Dafna Cap Limited Liability Company invested in 132,770 shs. Schwab Charles Inv Management Incorporated holds 182,345 shs.

Aerie Pharmaceuticals, Inc. registered $13.13 million net activity with 2 insider buys and 4 insider sales since May 21, 2018. Cagle Gerald D. bought 1,000 shs worth $50,245. On Thursday, May 24 Kopczynski Casey C. sold $135,806 worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 2,708 shs.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

A total of 6 analysts rate Aerie Pharma (NASDAQ:AERI) as follows: 6 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:AERI) has 10 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Wednesday, May 9 the firm earned “Buy” rating by Mizuho. In Friday, February 16 report H.C. Wainwright reinitiated it with “Buy” rating and $78 target. The company rating was maintained by Canaccord Genuity on Wednesday, January 24. On Thursday, March 1 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright. On Thursday, March 29 the firm earned “Buy” rating by Mizuho. On Wednesday, February 28 Cantor Fitzgerald maintained the shares of AERI in report with “Buy” rating. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. On Wednesday, May 9 H.C. Wainwright maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Tuesday, January 2 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Stifel Nicolaus. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

AERI reached $68.5 during the last trading session after $0.45 change.Currently Aerie Pharmaceuticals, Inc. is downtrending after 8.48% change in last June 27, 2017. AERI has 105,247 shares volume. AERI underperformed the S&P 500 by 21.05%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is worth $2.71 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

A couple more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were released by: Businesswire.com which released on June 18, 2018 “Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel”, also Businesswire.com on June 02, 2018 released “Aerie Pharmaceuticals to Present at the NASDAQ 38”, the next Gurufocus.com is “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares” on June 09, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap”.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: